Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first ...
Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...
The therapy may be eligible for a rare pediatric disease priority review voucher (PRV) if approved. Cyprium would retain ownership of this voucher, which could be used for a subsequent marketing ...
30, 2026, to receive vouchers for their qualifying drugs, after that, the FDA will no longer be allowed to give out priority review vouchers.
A decline in R&D investment in neglected tropical diseases threatens progress toward critical targets. For over 20 years, one ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses.
As described below, Cyprium is eligible to receive royalties and retains ownership of any Priority Review Voucher that may be issued. The CUTX-101 NDA submission is supported by positive topline ...
“With compelling Phase 2b osteosarcoma data, the anticipated FDA approval of OST-HER2, and the potential to earn a saleable Priority Review Voucher, the Company is positioned to unlock the full ...
Cyprium is eligible to receive royalties and will retain ownership of any priority review vouchers – a reward given to sponsors for firms that develop drugs to treat rare pediatric diseases ...